Catalent, Inc. (CTLT) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Somerset, NJ, United States. The current CEO is Alessandro Maselli.
CTLT has IPO date of 2014-07-31, 17,000 full-time employees, listed on the NYSE, a market capitalization of $11.52B.
Catalent, Inc. is a leading contract development and manufacturing organization that provides comprehensive solutions for drugs, biologics, cell and gene therapies, and consumer health products to pharmaceutical, biotechnology, and healthcare companies worldwide. Operating through four segments—Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services—the company offers specialized capabilities including softgel capsule manufacturing, biologic cell-line development, parenteral dose form production, oral delivery formulations, and clinical trial supply chain management. Its services span from early-stage formulation and development through commercial manufacturing and distribution, serving diverse markets including prescription and over-the-counter medications, dietary supplements, animal health products, and medical devices. Headquartered in Somerset, New Jersey, Catalent has established itself as a critical partner for companies seeking to bring innovative therapeutics and healthcare products to market efficiently and at scale.
